Intrinsic value of Novocure - NVCR

Previous Close

$31.39

  Intrinsic Value

$144.39

stock screener

  Rating & Target

str. buy

+360%

Previous close

$31.39

 
Intrinsic value

$144.39

 
Up/down potential

+360%

 
Rating

str. buy

We calculate the intrinsic value of NVCR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  283
  438
  654
  950
  1,340
  1,842
  2,472
  3,246
  4,177
  5,276
  6,551
  8,010
  9,655
  11,487
  13,507
  15,711
  18,098
  20,663
  23,402
  26,311
  29,386
  32,624
  36,022
  39,579
  43,294
  47,168
  51,203
  55,401
  59,765
  64,302
Variable operating expenses, $m
  136
  210
  314
  456
  643
  884
  1,187
  1,558
  2,005
  2,532
  3,145
  3,845
  4,634
  5,514
  6,483
  7,542
  8,687
  9,918
  11,233
  12,629
  14,105
  15,659
  17,290
  18,998
  20,781
  22,641
  24,577
  26,592
  28,687
  30,865
Fixed operating expenses, $m
  165
  168
  172
  176
  180
  183
  187
  192
  196
  200
  205
  209
  214
  218
  223
  228
  233
  238
  243
  249
  254
  260
  266
  271
  277
  283
  290
  296
  303
  309
Total operating expenses, $m
  301
  378
  486
  632
  823
  1,067
  1,374
  1,750
  2,201
  2,732
  3,350
  4,054
  4,848
  5,732
  6,706
  7,770
  8,920
  10,156
  11,476
  12,878
  14,359
  15,919
  17,556
  19,269
  21,058
  22,924
  24,867
  26,888
  28,990
  31,174
Operating income, $m
  -17
  59
  168
  318
  517
  774
  1,098
  1,496
  1,976
  2,543
  3,202
  3,956
  4,807
  5,755
  6,800
  7,942
  9,178
  10,507
  11,926
  13,433
  15,026
  16,704
  18,466
  20,310
  22,236
  24,244
  26,336
  28,512
  30,775
  33,128
EBITDA, $m
  -11
  68
  182
  338
  545
  813
  1,149
  1,564
  2,063
  2,653
  3,338
  4,123
  5,008
  5,994
  7,081
  8,269
  9,554
  10,936
  12,412
  13,980
  15,638
  17,383
  19,215
  21,133
  23,136
  25,225
  27,401
  29,665
  32,018
  34,465
Interest expense (income), $m
  7
  9
  13
  22
  36
  54
  79
  111
  150
  199
  257
  326
  406
  498
  601
  716
  843
  982
  1,132
  1,293
  1,465
  1,648
  1,841
  2,044
  2,258
  2,481
  2,715
  2,958
  3,211
  3,475
  3,749
Earnings before tax, $m
  -27
  47
  146
  282
  463
  695
  988
  1,346
  1,777
  2,286
  2,876
  3,550
  4,309
  5,154
  6,084
  7,099
  8,196
  9,375
  10,633
  11,968
  13,379
  14,864
  16,421
  18,052
  19,754
  21,529
  23,378
  25,301
  27,300
  29,378
Tax expense, $m
  0
  13
  39
  76
  125
  188
  267
  363
  480
  617
  777
  958
  1,163
  1,391
  1,643
  1,917
  2,213
  2,531
  2,871
  3,231
  3,612
  4,013
  4,434
  4,874
  5,334
  5,813
  6,312
  6,831
  7,371
  7,932
Net income, $m
  -27
  34
  107
  206
  338
  508
  721
  983
  1,298
  1,669
  2,099
  2,591
  3,145
  3,762
  4,441
  5,182
  5,983
  6,844
  7,762
  8,737
  9,766
  10,850
  11,988
  13,178
  14,421
  15,716
  17,066
  18,470
  19,929
  21,446

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  208
  322
  481
  698
  984
  1,353
  1,816
  2,385
  3,069
  3,876
  4,814
  5,885
  7,094
  8,440
  9,924
  11,544
  13,298
  15,182
  17,195
  19,332
  21,591
  23,970
  26,467
  29,081
  31,811
  34,657
  37,622
  40,706
  43,913
  47,246
Adjusted assets (=assets-cash), $m
  208
  322
  481
  698
  984
  1,353
  1,816
  2,385
  3,069
  3,876
  4,814
  5,885
  7,094
  8,440
  9,924
  11,544
  13,298
  15,182
  17,195
  19,332
  21,591
  23,970
  26,467
  29,081
  31,811
  34,657
  37,622
  40,706
  43,913
  47,246
Revenue / Adjusted assets
  1.361
  1.360
  1.360
  1.361
  1.362
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
  1.361
Average production assets, $m
  29
  46
  68
  99
  139
  192
  257
  338
  434
  549
  681
  833
  1,004
  1,195
  1,405
  1,634
  1,882
  2,149
  2,434
  2,736
  3,056
  3,393
  3,746
  4,116
  4,503
  4,906
  5,325
  5,762
  6,216
  6,687
Working capital, $m
  15
  24
  35
  51
  72
  99
  133
  175
  226
  285
  354
  433
  521
  620
  729
  848
  977
  1,116
  1,264
  1,421
  1,587
  1,762
  1,945
  2,137
  2,338
  2,547
  2,765
  2,992
  3,227
  3,472
Total debt, $m
  133
  235
  378
  574
  832
  1,164
  1,580
  2,092
  2,708
  3,434
  4,278
  5,242
  6,330
  7,542
  8,877
  10,335
  11,914
  13,610
  15,421
  17,345
  19,378
  21,519
  23,766
  26,118
  28,575
  31,137
  33,805
  36,581
  39,467
  42,467
Total liabilities, $m
  187
  289
  433
  628
  886
  1,218
  1,635
  2,147
  2,762
  3,489
  4,332
  5,297
  6,384
  7,596
  8,932
  10,390
  11,968
  13,664
  15,475
  17,399
  19,432
  21,573
  23,820
  26,173
  28,630
  31,191
  33,859
  36,635
  39,522
  42,521
Total equity, $m
  21
  32
  48
  70
  98
  135
  182
  239
  307
  388
  481
  589
  709
  844
  992
  1,154
  1,330
  1,518
  1,719
  1,933
  2,159
  2,397
  2,647
  2,908
  3,181
  3,466
  3,762
  4,071
  4,391
  4,725
Total liabilities and equity, $m
  208
  321
  481
  698
  984
  1,353
  1,817
  2,386
  3,069
  3,877
  4,813
  5,886
  7,093
  8,440
  9,924
  11,544
  13,298
  15,182
  17,194
  19,332
  21,591
  23,970
  26,467
  29,081
  31,811
  34,657
  37,621
  40,706
  43,913
  47,246
Debt-to-equity ratio
  6.390
  7.310
  7.870
  8.220
  8.450
  8.600
  8.700
  8.770
  8.820
  8.860
  8.890
  8.910
  8.920
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -27
  34
  107
  206
  338
  508
  721
  983
  1,298
  1,669
  2,099
  2,591
  3,145
  3,762
  4,441
  5,182
  5,983
  6,844
  7,762
  8,737
  9,766
  10,850
  11,988
  13,178
  14,421
  15,716
  17,066
  18,470
  19,929
  21,446
Depreciation, amort., depletion, $m
  6
  9
  14
  20
  28
  38
  51
  68
  87
  110
  136
  167
  201
  239
  281
  327
  376
  430
  487
  547
  611
  679
  749
  823
  901
  981
  1,065
  1,152
  1,243
  1,337
Funds from operations, $m
  -21
  43
  120
  226
  366
  546
  772
  1,050
  1,384
  1,779
  2,236
  2,758
  3,346
  4,001
  4,722
  5,509
  6,360
  7,273
  8,249
  9,284
  10,378
  11,529
  12,737
  14,001
  15,321
  16,698
  18,131
  19,622
  21,172
  22,784
Change in working capital, $m
  6
  8
  12
  16
  21
  27
  34
  42
  50
  59
  69
  79
  89
  99
  109
  119
  129
  139
  148
  157
  166
  175
  184
  192
  201
  209
  218
  227
  236
  245
Cash from operations, $m
  -26
  35
  109
  210
  345
  519
  738
  1,008
  1,334
  1,719
  2,167
  2,679
  3,257
  3,902
  4,613
  5,390
  6,231
  7,135
  8,101
  9,127
  10,212
  11,354
  12,553
  13,809
  15,121
  16,488
  17,913
  19,395
  20,937
  22,539
Maintenance CAPEX, $m
  -4
  -6
  -9
  -14
  -20
  -28
  -38
  -51
  -68
  -87
  -110
  -136
  -167
  -201
  -239
  -281
  -327
  -376
  -430
  -487
  -547
  -611
  -679
  -749
  -823
  -901
  -981
  -1,065
  -1,152
  -1,243
New CAPEX, $m
  -11
  -16
  -23
  -31
  -41
  -52
  -66
  -80
  -97
  -114
  -133
  -152
  -171
  -191
  -210
  -229
  -248
  -267
  -285
  -303
  -320
  -337
  -353
  -370
  -386
  -403
  -420
  -437
  -454
  -472
Cash from investing activities, $m
  -15
  -22
  -32
  -45
  -61
  -80
  -104
  -131
  -165
  -201
  -243
  -288
  -338
  -392
  -449
  -510
  -575
  -643
  -715
  -790
  -867
  -948
  -1,032
  -1,119
  -1,209
  -1,304
  -1,401
  -1,502
  -1,606
  -1,715
Free cash flow, $m
  -41
  13
  77
  166
  284
  439
  634
  877
  1,170
  1,518
  1,924
  2,391
  2,920
  3,511
  4,164
  4,879
  5,656
  6,492
  7,386
  8,338
  9,345
  10,406
  11,521
  12,690
  13,911
  15,185
  16,512
  17,894
  19,330
  20,824
Issuance/(repayment) of debt, $m
  36
  102
  143
  195
  258
  332
  417
  512
  616
  727
  844
  964
  1,088
  1,212
  1,336
  1,458
  1,578
  1,696
  1,811
  1,924
  2,033
  2,141
  2,247
  2,352
  2,457
  2,562
  2,668
  2,776
  2,886
  3,000
Issuance/(repurchase) of shares, $m
  69
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  105
  102
  143
  195
  258
  332
  417
  512
  616
  727
  844
  964
  1,088
  1,212
  1,336
  1,458
  1,578
  1,696
  1,811
  1,924
  2,033
  2,141
  2,247
  2,352
  2,457
  2,562
  2,668
  2,776
  2,886
  3,000
Total cash flow (excl. dividends), $m
  64
  115
  220
  361
  542
  771
  1,051
  1,388
  1,785
  2,245
  2,768
  3,356
  4,007
  4,722
  5,500
  6,337
  7,234
  8,188
  9,197
  10,261
  11,378
  12,547
  13,769
  15,042
  16,368
  17,747
  19,180
  20,670
  22,217
  23,824
Retained Cash Flow (-), $m
  -69
  -11
  -16
  -22
  -29
  -37
  -46
  -57
  -68
  -81
  -94
  -107
  -121
  -135
  -148
  -162
  -175
  -188
  -201
  -214
  -226
  -238
  -250
  -261
  -273
  -285
  -296
  -308
  -321
  -333
Prev. year cash balance distribution, $m
  135
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  130
  104
  204
  339
  514
  734
  1,005
  1,332
  1,717
  2,164
  2,674
  3,248
  3,886
  4,588
  5,351
  6,175
  7,059
  7,999
  8,996
  10,047
  11,152
  12,309
  13,519
  14,781
  16,095
  17,462
  18,884
  20,361
  21,896
  23,490
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  124
  95
  178
  279
  398
  533
  679
  832
  986
  1,135
  1,270
  1,386
  1,478
  1,540
  1,571
  1,569
  1,536
  1,473
  1,385
  1,277
  1,153
  1,021
  886
  753
  626
  509
  405
  315
  239
  177
Current shareholders' claim on cash, %
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

FINANCIAL RATIOS  of  Novocure (NVCR)

Valuation Ratios
P/E Ratio -20.7
Price to Sales 32.9
Price to Book 19.2
Price to Tangible Book
Price to Cash Flow -25.3
Price to Free Cash Flow -21.7
Growth Rates
Sales Growth Rate 151.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 80%
Cap. Spend. - 3 Yr. Gr. Rate 35.1%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 67.6%
Total Debt to Equity 67.6%
Interest Coverage -16
Management Effectiveness
Return On Assets -42.2%
Ret/ On Assets - 3 Yr. Avg. -48.9%
Return On Total Capital -51.6%
Ret/ On T. Cap. - 3 Yr. Avg. -57.3%
Return On Equity -67.2%
Return On Equity - 3 Yr. Avg. -63.8%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 51.8%
Gross Margin - 3 Yr. Avg. 40.5%
EBITDA Margin -130.1%
EBITDA Margin - 3 Yr. Avg. -319.7%
Operating Margin -138.6%
Oper. Margin - 3 Yr. Avg. -331.2%
Pre-Tax Margin -145.8%
Pre-Tax Margin - 3 Yr. Avg. -334.5%
Net Profit Margin -159%
Net Profit Margin - 3 Yr. Avg. -346.1%
Effective Tax Rate -9.1%
Eff/ Tax Rate - 3 Yr. Avg. -5%
Payout Ratio 0%

NVCR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NVCR stock intrinsic value calculation we used $177.026 million for the last fiscal year's total revenue generated by Novocure. The default revenue input number comes from 0001 income statement of Novocure. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NVCR stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for NVCR is calculated based on our internal credit rating of Novocure, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Novocure.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NVCR stock the variable cost ratio is equal to 48%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $161 million in the base year in the intrinsic value calculation for NVCR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.5% for Novocure.

Corporate tax rate of 27% is the nominal tax rate for Novocure. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NVCR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NVCR are equal to 10.4%.

Life of production assets of 2.4 years is the average useful life of capital assets used in Novocure operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NVCR is equal to 5.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $113.564 million for Novocure - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 90.699 million for Novocure is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Novocure at the current share price and the inputted number of shares is $2.8 billion.

RELATED COMPANIES Price Int.Val. Rating
CLDX Celldex Therap 0.340 0.12  str.sell
ISR IsoRay 0.410 0.05  str.sell
SRTS Sensus Healthc 6.04 0.21  str.sell
ARAY Accuray 4.76 0.76  str.sell
VRAY ViewRay 6.28 0.01  str.sell
ICAD icad 2.81 0.06  str.sell
VAR Varian Medical 117.42 77.55  sell

COMPANY NEWS

▶ Zai Lab and Novocure Awarded Deal of the Year   [Nov-14-18 07:30AM  GlobeNewswire]
▶ 3 Top Healthcare Stocks to Buy in November   [Nov-13-18 08:01PM  Motley Fool]
▶ Novocure and Zai Lab to Host Investor Event   [Nov-07-18 04:00PM  Business Wire]
▶ Here's Why NovoCure Fell 36.8% in October   [11:22AM  Motley Fool]
▶ Here's Why Novocure Is Tumbling Today   [Oct-25-18 03:11PM  Motley Fool]
▶ Why Novocure Stock Jumped 16.3% in September   [Oct-11-18 08:03AM  Motley Fool]
▶ 3 Medical Devices Stocks to Buy   [Oct-02-18 11:51AM  InvestorPlace]
▶ Novocure to Report Third Quarter 2018 Financial Results   [Oct-01-18 08:36AM  Business Wire]
▶ 5 Medical Device Stocks With Impressive Staying Power   [Sep-13-18 10:57AM  InvestorPlace]
▶ Why Novocure Gained 33% in August   [Sep-10-18 10:31AM  Motley Fool]
▶ This brain cancer drug stock has been on a tear   [Aug-31-18 04:38PM  Yahoo Finance]
▶ 3 Small-Cap Healthcare Stocks for Your Watch List   [Aug-26-18 07:15PM  Motley Fool]
▶ Benzinga Pro's 5 Stocks To Watch Today   [Aug-15-18 08:38AM  Benzinga]
▶ Forget Bitcoin: You're Better Off Buying These 3 Stocks   [Aug-06-18 12:18PM  Motley Fool]
▶ Novocure to Present at Two Upcoming Investor Conferences   [Aug-03-18 07:30AM  Business Wire]
▶ Novocure Announces Addition to Its Board of Directors   [Aug-02-18 07:30AM  Business Wire]
▶ NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%   [Jul-17-18 08:54AM  Zacks]
▶ Trade of the Day: Novocure Ltd (NVCR)   [Jul-06-18 09:13AM  InvestorPlace]
▶ Novocure Appoints Pritesh Shah as Chief Commercial Officer   [Jul-02-18 08:00AM  Business Wire]
▶ NovoCure's Charts Look Bullish   [Jun-21-18 02:40PM  TheStreet.com]
▶ Novocure Announces Changes to Its Board of Directors   [May-31-18 04:05PM  Business Wire]
▶ Best Growth Stock in May   [May-14-18 12:02PM  Simply Wall St.]
▶ This Explains Why NovoCure Is Surging Today   [Apr-26-18 04:53PM  Motley Fool]
▶ NovoCure: 1Q Earnings Snapshot   [11:55AM  Associated Press]
▶ Novocure Ltd. to Host Earnings Call   [06:00AM  ACCESSWIRE]
▶ 3 Top Healthcare Stocks to Buy in April   [Apr-13-18 06:31PM  Motley Fool]
▶ Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR)   [Mar-15-18 05:42PM  Simply Wall St.]
▶ NovoCure reports 4Q loss   [Feb-22-18 07:30AM  Associated Press]
▶ Novocure Ltd. to Host Earnings Call   [06:00AM  ACCESSWIRE]
▶ Who Really Owns NovoCure Limited (NASDAQ:NVCR)?   [Feb-13-18 05:19PM  Simply Wall St.]
▶ Here's Why NovoCure Popped 157% in 2017   [Jan-09-18 10:53AM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.